EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma

Ian D Pavord, Thomas B Casale, Jonathan Corren, Mark J FitzGerald, Yamo Deniz, Arman Altincatal, Rebecca Gall, Nami Pandit-Abid, Amr Radwan, Juby A Jacob-Nara, Paul J Rowe, William W Busse

The Journal of Allergy and Clinical Immunology: In Practice · 2024

DOI: 10.1016/j.jaip.2024.03.031 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024. Verfasst von Ian D Pavord und 11 weiteren Autor:innen. Beteiligte Einrichtung: NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom. Electronic address: ian.pavord@ndm.ox.ac.uk. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Biomarkers, Eosinophils. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regeneron Pharmaceuticals Inc, Sanofi US.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Changes from baseline in fractional exhaled nitric oxide (FeNO) and blood eosinophil count (Eos) may be related to efficacy outcomes in dupilumab-treated patients with moderate-to-severe asthma. OBJECTIVE: This post hoc analysis investigated biomarker changes in placebo- and dupilumab-treated patients with uncontrolled moderate-to-severe asthma enrolled in QUEST (NCT02414854). METHODS: Spline analyses of annualized severe exacerbation rate (AER) and change from baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) at week 52 were performed as a function of the fold change in FeNO at week 52 and the maximum fold change in Eos over weeks 0-12 (also change from baseline in pre-BD FEV1 at week 12). RESULTS: The combined placebo and dupilumab groups comprised 638 and 1264 patients, respectively. FeNO levels declined rapidly by week 2 and then gradually to week 52 in patients treated with dupilumab versus placebo; Eos, after initially increasing with dupilumab, declined slightly from baseline in both treatment groups. AER during QUEST showed no significant association with the change in biomarkers in either treatment group. The change from baseline in pre-BD FEV1 at week 52 was inversely associated with the fold change in FeNO in both groups, with a significant difference between the dupilumab and placebo curves (P = .014), and was positively associated with the fold change in Eos in both groups (P = .022). CONCLUSIONS: Relative changes in FeNO and Eos were not associated with AER, regardless of treatment arm. However, changes in both biomarkers showed a predictive value for lung function improvement; for FeNO, this was specific to the dupilumab treatment arm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAntibodies, Monoclonal, HumanizedBiomarkersEosinophilsNitric OxideAnti-Asthmatic AgentsHumansMaleFemaleAdultMiddle AgedForced Expiratory VolumeSeverity of Illness IndexDouble-Blind MethodTreatment OutcomeDisease ProgressionLeukocyte Count

Stichwörter der Autor:innen

EosinophilsExacerbationsFractional exhaled nitric oxideLung function

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedBiomarkersNitric OxideAnti-Asthmatic Agents

Autor:innen und Institutionen

  • NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom. Electronic address: ian.pavord@ndm.ox.ac.uk.
  • Division of Allergy and Immunology, University of South Florida, Tampa, Fla.
  • David Geffen School of Medicine, University of California, Los Angeles, CA.
  • University of British Columbia, Vancouver, BC, Canada.
  • Regeneron Pharmaceuticals, Inc, Tarrytown, NY.
  • Sanofi, Cambridge, Mass.

Förderung

  • Regeneron Pharmaceuticals Inc
  • Sanofi US

Zitieren

APA

Pavord, I. D., Casale, T. B., Corren, J., FitzGerald, M. J., Deniz, Y., Altincatal, A., Gall, R., Pandit-Abid, N., Radwan, A., Jacob-Nara, J. A., Rowe, P. J., & Busse, W. W. (2024). Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2024.03.031

Vancouver

Pavord ID, Casale TB, Corren J, FitzGerald MJ, Deniz Y, Altincatal A, et al. Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma. The Journal of Allergy and Clinical Immunology: In Practice. 2024. doi:10.1016/j.jaip.2024.03.031

BibTeX
@article{Pavord2024,
  author = {Pavord, Ian D and Casale, Thomas B and Corren, Jonathan and FitzGerald, Mark J and Deniz, Yamo and Altincatal, Arman and Gall, Rebecca and Pandit-Abid, Nami and Radwan, Amr and Jacob-Nara, Juby A and Rowe, Paul J and Busse, William W},
  title = {Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2024},
  doi = {10.1016/j.jaip.2024.03.031}
}
Kostenlos starten →